To the full analysis
Neurones stock: growth
NRO.PANeurones reported $949.86M in revenue for fiscal 2025, up 5.8% on the prior year, up 10.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
10.4%
per year from 2006 to 2025, per share 9.2%
Earnings (Annual rate)
11.5%
per year from 2006 to 2025, per share 11.7%
Free cash flow (Annual rate)
19.9%
per year from 2006 to 2025, per share 18.5%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 10.3% | 7.9% | 10.4% |
| Revenue per share | 6.5% | 6.0% | 9.2% |
| Earnings | 11.0% | 9.3% | 11.5% |
| Earnings per share | 11.0% | 9.2% | 11.7% |
| Free cash flow | 2.6% | 15.1% | 19.9% |
| Free cash flow per share | −0.9% | 13.1% | 18.5% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $144.02M | $7.31M | $2.48M |
| 2007 | $172.84M | $11.02M | $14.38M |
| 2008 | $209.79M | $14.38M | $15.95M |
| 2009 | $239.78M | $14.2M | $14.86M |
| 2010 | $265.47M | $16.55M | $14.05M |
| 2011 | $313.94M | $16.4M | $3.78M |
| 2012 | $349.5M | $16.45M | $16.34M |
| 2013 | $380.26M | $20.58M | $16.09M |
| 2014 | $393.56M | $22.72M | $25.81M |
| 2015 | $442.54M | $23.67M | $19.06M |
| 2016 | $495.05M | $27.92M | $13.91M |
| 2017 | $537.44M | $30.26M | $15.86M |
| 2018 | $543.05M | $28.77M | $26.72M |
| 2019 | $565.21M | $34.13M | $59.34M |
| 2020 | $581.19M | $34.26M | $68.48M |
| 2021 | $642.56M | $41.78M | $64.39M |
| 2022 | $737.31M | $49.03M | $49.13M |
| 2023 | $821.3M | $54.75M | $59.94M |
| 2024 | $898M | $58.18M | $80.17M |
| 2025 | $949.86M | $57.7M | $77.94M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 17 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.